Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
6 studies found for:    Reslizumab | asthma | Phase 3

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab;   Drug: Placebo
2 Completed Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab;   Drug: Matching Placebo
3 Terminated Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
Condition: Eosinophilic Asthma
Intervention: Drug: Reslizumab
4 Completed A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab;   Drug: Placebo
5 Completed A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab;   Drug: Placebo
6 Recruiting Cross-sectional Study for Identification and Description of Severe Asthma Patients
Condition: Asthma
Intervention: Drug: Short Acting Beta Agonist (SABA)
To Top

† Indicates status has not been verified in more than two years